6,200 Multi-Country Physicians on COVID-19 Uncovers Treatment Patterns and Puts Pandemic in Context

▴ 6200 MultiCountry Physicians on COVID19 Uncovers Treatment Patterns and Puts Pandemic in Context
In the U.S., 63% of physicians recommend restrictions be lifted six or more weeks from now and 66% believe the peak is at least 3-4 weeks away

Widespread confusion, conflicting reports, inconsistent testing, and off-indication use of existing and experimental drugs has resulted in no single source of information from the frontlines. To create a centralized and dynamic knowledge base, Sermo, the largest global healthcare polling company and social platform for physicians, leveraged its capabilities to publish results of a COVID-19 study with more than 6,200 physicians in 30 countries. The study was completed in three days. Data covers current treatment and prophylaxis options, timing to the outbreak peak, ethical choices, effectiveness of government responses, and much more. Multiple study waves including a deeper dive into treatments will be conducted over the next several weeks.


Treatments & Efficacy

The three most commonly prescribed treatments amongst COVID-19 treaters are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine


Hydroxychloroquine usage amongst COVID-19 treaters is 72% in Spain, 49% in Italy, 41% in Brazil, 39% in Mexico, 28% in France, 23% in the U.S., 17% in Germany, 16% in Canada, 13% in the UK, and 7% in Japan


Hydroxychloroquine was overall chosen as the most effective therapy amongst COVID-19 treaters from a list of 15 options. (37% of COVID-19 treaters)


75% in Spain, 53% Italy, 44% in China, 43% in Brazil, 29% in France, 23% in the U.S., and 13% in the UK


The two most common treatment regimens for Hydroxychloroquine were:
(38%) 400mg twice daily on day one; 400 mg daily for five days
(26%) 400mg twice daily on day one; 200mg twice daily for four days

Outside the U.S., Hydroxychloroquine was equally used for diagnosed patients with mild to severe symptoms whereas in the U.S. it was most commonly used for high risk diagnosed patients
Globally, 19% of physicians prescribed or have seen Hydroxychloroquine prophylactically used for high risk patients, and 8% for low risk patients

Second Wave of Outbreak


The second global outbreak is anticipated by 83% of global physicians, 90% of U.S. physicians but only 50% of Chinese physicians

Average Testing Time


On average tests in the U.S. take 4-5 days, and in 10% of cases the wait is more than 7 days
14% of U.S. physicians and over 50% in all of Europe and Japan report getting test results in 24 hours; in China 73% of doctors get tests back in 24 hours, while 8% get tests back within the hour

Prioritizing Treatment if Ventilator Shortage


In all countries except China, the top criteria for deciding who should receive a ventilator first was patients with the highest chance of recovery (47%) followed by those most ill and at highest risk of death (21%), then first responders (15%)
In China the priorities were reversed as the most ill and highest risk of death received ventilators
First responders were more important in the U.S.
France, Japan, and Italy prioritized age
Brazil and Russia prioritized higher risk patients

Peak Timing & Restrictions


In the U.S., 63% of physicians recommend restrictions be lifted six or more weeks from now and 66% believe the peak is at least 3-4 weeks away


“This is a treasure trove of global insights for policy makers. Physicians should have more of a voice in how we deal with this pandemic and be able to quickly share information with one another and the world,” said Peter Kirk, CEO, Sermo. “With censorship of the media and the medical community in some countries, along with biased and poorly designed studies, solutions to the pandemic are being delayed. We invite global physicians to contribute to help inform policy makers, their colleagues, and the public.”

Tags : #covid19 #treatmentpatterns #6200doctors #smitakumar #Doctors-Speak

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Transforming Brain Healthcare: India's Visionary Task Force for Neurological DisordersApril 25, 2024
The Battle Against Malaria: Rising Trends and Vaccine InnovationsApril 25, 2024
Talc and Asbestos Controversy: Inside Johnson & Johnson's Courtroom StruggleApril 25, 2024
The Hidden Struggles of Parenthood: Addressing Isolation, Loneliness, and BurnoutApril 25, 2024
FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024
10 Strategies to counter disinformation for the healthcare digital ecosystemApril 23, 2024
Is Selling Over-the-Counter (OTC) Drugs in General Stores A Step Towards Affordable Healthcare in IndiaApril 23, 2024
Student Health Crisis: Food Poisoning Incident Strikes Pune Coaching CentreApril 23, 2024
The Impact of Diabetes on Kidney Health: Diabetic Nephropathy ExplainedApril 23, 2024
Toddler Hospitalized After Consuming Expired Chocolates: Health Concerns RaisedApril 23, 2024
After months of diagnostic delay, a migrant worker could access TB services only when a community health worker met himApril 22, 2024
Indian Spices Contaminated with Cancer-Causing Chemical: Hong Kong Food Regulators Issue WarningApril 22, 2024
FTCCI organised a Workshop on Rooftop Kitchen GardeningApril 20, 2024
Children in Cities Exposed to Elevated Lead Levels: Study Reveals Urgent Health ConcernApril 20, 2024
Biocon Ventures into Weight-Loss Drug Market with Semaglutide DevelopmentApril 20, 2024
Innovative AI Assistance Empowers Moscow Doctors to Detect Cervical Spine Issues through MRI ScansApril 20, 2024
Air India Express ties up with AISATS for AeroWash Automated Aircraft Exterior Cleanings April 19, 2024
IndoSup raises strategic funding led by CCI group promoters Naresh Sharma and Satish Sharma; investors include Yatra.com’s Rohan Mittal April 19, 2024